[Diphenylhydantoin stimulation test in Wilson's disease].
Coeruloplasmin and diphenylhydantoin levels were studied both in patients who were stabilised for the first time on diphenylhyantoin (300 mg daily) up to reaching a stable serum concentration (N = 6) and during steady-state concentration (N = 25). No significant DPH-dependent influence on the coeruloplasmin level in the serum was found. In our opinion, DPH is no suitable for the stimulation of coeruloplasmin and thus for the diagnosis of Wilson's disease, particularly in the preclinical stage, because absence of coeruloplasmin increase in the serum being found also in healthy persons.
D000328:Adult; D002570:Ceruloplasmin / Q000032:analysis; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy; D005260:Female; D006527:Hepatolenticular Degeneration / Q000097:blood / Q000175:diagnosis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000097:blood / Q000627:therapeutic use
D010672:Phenytoin; D002570:Ceruloplasmin
Zur Frage eines sogenannten Diphenylhydantoin-Stimulationstestes bei Wilsonscher Erkrankung.